期刊
PLOS ONE
卷 12, 期 2, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0172177
关键词
-
资金
- Leukemia and Lymphoma Society
- Burroughs-Wellcome Fund
- Pershing Square Sohn Cancer Research Alliance
- Starr Cancer Consortium
- NIH/NCI [R01 CA174793]
- Stand Up To Cancer Philip A. Sharp Awards
- old Spring Harbor Laboratory Sponsored Research
- Simons Center for Quantitative Biology at Cold Spring Harbor Laboratory
- Cold Spring Harbor Laboratory Women in Science Award
Genetic alterations conferring resistance to the effects of chemical inhibitors are valuable tools for validating on-target effects in cells. Unfortunately, for many therapeutic targets such alleles are not available. To address this issue, we evaluated whether CRISPR-Cas9mediated insertion/deletion (indel) mutagenesis can produce drug-resistance alleles at endogenous loci. This method takes advantage of the heterogeneous in-frame alleles produced following Cas9-mediated DNA cleavage, which we show can generate rare alleles that confer resistance to the growth-arrest caused by chemical inhibitors. We used this approach to identify novel resistance alleles of two lysine methyltransferases, DOT1L and EZH2, which are each essential for the growth of MLL-fusion leukemia cells. We biochemically characterized the DOT1L mutation, showing that it is significantly more active than the wild-type enzyme. These findings validate the on-target anti-leukemia activities of existing DOT1L and EZH2 inhibitors and reveal a simple method for deriving drug-resistance alleles for novel targets, which may have utility during early stages of drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据